Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort

Disparities in dolutegravir utilisation in children, adolescents and young adults (0–24 years) living with HIV. An analysis of the IeDEA Pediatric West African cohort

Introduction We describe the 24-month incidence of Dolutegravir (DTG)-containing antiretroviral treatment (ART) initiation since its introduction in 2019 in West Africa.Methods We included all patients aged 0–24 years on ART from nine clinics in Côte d’Ivoire (n=4), Ghana, Nigeria, Mali, Benin, and...

Full description

Saved in:
Bibliographic Details
Main Authors: Valériane Leroy, Anandi Sheth, Julie Jesson, Jean Jacques Koffi, Antoine Jaquet, François Dabis, Didier Koumavi Ekouevi, Karen Malateste, Olivia Keiser, Lehila Bagnan, Simon Boni, Madeleine Amorissani Folquet, Mariam Sylla, Olivier Marcy, Raoul Moh, Gildas Boris Hedible, Sophie Desmonde, Joycelyn Dame, Agatha David, Madeleine Amorissani-Folquet, Sylvie N'Gbeche, Elom Takassi, François Tanoh Eboua, Kouadio Kouakou, Lehila Bagnan Tossa, Caroline Yonaba, Jocelyn Dame, Sylvie Marie N’Gbeche, Fatoumata Dicko Traore, Oliver Ezchechi, Rosemary Audu, Charlotte Bernard, Caroline Couturier, Marie Kerbie Plaisy, Elodie Rabourdin, Thierry Tiendrebeogo, Désiré Dahourou, Emile Sodinyessi, Jean-Claude Azani, Kadidja Diarra, Maika Bengali, Abdoulaye Cissé, Guy Gnepa, Eric Komena, Séverin Lenaud, Eulalie Kangah, Igho Ofotokun, Cecile Delille Lahiri, Noëlle Benzekri, Geoffrey Gottlieb
Format: Article
Language:English
Published: BMJ Publishing Group 2025-01-01
Series:BMJ Global Health
Online Access:https://gh.bmj.com/content/10/1/e016512.full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items